Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1\textsuperscript{G93A} mouse model of amyotrophic lateral sclerosis

John D. Lee\textsuperscript{1,2}, Ning Liu\textsuperscript{1}, Samantha C. Levin\textsuperscript{1}, Lars Ottosson\textsuperscript{3}, Ulf Andersson\textsuperscript{3}, Helena E. Harris\textsuperscript{4} and Trent M. Woodruff\textsuperscript{1*}

Abstract

**Background:** Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing neurodegenerative disease without effective treatment. The receptor for advanced glycation end products (RAGE) and the toll-like receptor (TLR) system are major components of the innate immune system, which have been implicated in ALS pathology. Extracellularly released high-mobility group box 1 (HMGB1) is a pleiotropic danger-associated molecular pattern (DAMP), and is an endogenous ligand for both RAGE and TLR4.

**Methods:** The present study examined the effect of HMGB1 inhibition on disease progression in the preclinical SOD1\textsuperscript{G93A} transgenic mouse model of ALS using a potent anti-HMGB1 antibody (2G7), which targets the extracellular DAMP form of HMGB1.

**Results:** We found that chronic intraperitoneal dosing of the anti-HMGB1 antibody to SOD1\textsuperscript{G93A} mice transiently improved hind-limb grip strength early in the disease, but did not extend survival. Anti-HMGB1 treatment also reduced tumour necrosis factor \(\alpha\) and complement C5a receptor 1 gene expression in the spinal cord, but did not affect overall glial activation.

**Conclusions:** In summary, our results indicate that therapeutic targeting of an extracellular DAMP, HMGB1, improves early motor dysfunction, but overall has limited efficacy in the SOD1\textsuperscript{G93A} mouse model of ALS.

**Keywords:** TLR4, RAGE, Neuroinflammation, Innate immune system

Background

Amyotrophic lateral sclerosis (ALS) is an adult onset neurodegenerative disease, which is characterised by the irreversible loss of upper and lower motor neurons in the motor cortex, brainstem and spinal cord. This selective loss of neurons leads to muscle denervation, and atrophy, resulting in paralysis and eventual death via respiratory muscle failure [1]. The mechanisms underlying ALS pathogenesis are still unclear, but an emerging body of evidence suggests that immune and inflammatory factors could contribute to the progression of the disease [2–4].

The receptor for advanced glycation end products (RAGE), the toll-like receptor (TLR) system and the complement C5a receptor 1 (C5aR1) are major components of the innate immune system, which have been implicated in ALS pathology. RAGE and TLR4 are generally considered pro-inflammatory receptors expressed by numerous immune and non-immune cells, including cells within the central nervous system (CNS) [5, 6]. Multiple studies have demonstrated that inhibition and/or genetic deletion of RAGE, TLR4, or C5aR1 has beneficial effects on survival and disease progression in animal models of ALS [6–11], suggesting that these immune receptors play a pathogenic role in the disease.
Extracellularly released high-mobility group box 1 (HMGB1) is a pleiotropic danger-associated molecular pattern (DAMP), and is an endogenous ligand for both RAGE and TLR4. HMGB1 is passively released by damaged cells or secreted from activated immune cells into the extracellular milieu, driving inflammatory response in numerous inflammatory diseases, and can be blocked by antibodies specific for the extracellular DAMP form of HMGB1. RAGE and TLR4 activation through the disulfide form of HMGB1 can induce neuroinflammation by releasing cytokines such as tumour necrosis factor-α and interleukins, which have been shown to be involved in ALS pathogenesis [7, 12]. Extracellular HMGB1 can also bind to DNA, lipopolysaccharide and many other immune-activating molecules such as cytokines (IL-1α and IL-1β), which can initiate and mediate inflammatory responses by allowing interactions with a greater number of pro-inflammatory cytosolic receptors [13–15]. Importantly, HMGB1 has been shown to translocate from the nucleus to the cytoplasm in reactive astrocytes and microglia in ALS patients and mouse models [6, 16, 17], suggesting a potential pathogenic role for HMGB1 in ALS.

Since RAGE, TLR4 and HMGB1 are all upregulated in ALS, we hypothesised that therapeutic targeting of the extracellular HMGB1 could be neuroprotective in this disease. To test this, we examined the effect of HMGB1 inhibition on disease progression in the preclinical SOD1G93A transgenic mouse model of ALS using a potent anti-HMGB1 antibody (2G7), which targets the extracellular DAMP form of HMGB1. We found that chronic intraperitoneal dosing of the anti-HMGB1 antibody to SOD1G93A mice transiently improved hind-limb grip strength early in the disease process, but did not extend survival. Anti-HMGB1 treatment also reduced TNFα and C5αR1 gene expression in the spinal cord, but did not affect overall glial activation. In summary, our results indicate that therapeutic targeting of extracellular DAMP, HMGB1 signalling protects against early motor dysfunction, but overall has limited efficacy in the SOD1G93A mouse model of ALS.

Methods

Animals

Transgenic SOD1G93A mice (B6-Cg-Tg (SOD1-G93A) 1Gur/1) expressing the high copy number (~25 copies) of mutant human SOD1 on a C57BL/6J background were initially obtained from Jackson laboratory (Bar Harbor, ME, USA). A breeding colony was maintained at the University of Queensland Biological Resources Animal Facilities under specific pathogen-free conditions. For all therapeutic efficacy studies, female SOD1G93A littermates (i.e. paired mice from the same litter) were used and separated using a simple randomisation procedure (coin toss) to receive either isotype control antibody, or anti-HMGB1 antibody treatment, in a blinded manner. Transgene copy number for SOD1G93A mice was verified by quantitative PCR as previously described [18]. All animals were group housed (2–3 mice/cage) under identical conditions in a 12 h light/dark cycle (lights on at 0630) with free access to food and water.

Anti-HMGB1 antibody treatment

Monoclonal humanised anti-HMGB1 antibody (clone 2G7, IgG2b) has previously been characterised to show neutralising activity of HMGB1 [19]. For early treatment, anti-HMGB1 antibody (produced from a hybridoma at Karolinska Institutet) was administered weekly to mice via intraperitoneal injection (100 μg/mouse injection). Litter-matched female SOD1G93A transgenic mice were administered with control IgG2b (vehicle; Innovagen, Lund, Sweden) or anti-HMGB1 antibody prophylactically from 35 days postnatal (termed ‘pre-onset’). For therapeutic treatment, anti-HMGB1 antibody or control IgG2b were administered from 70 days postnatal, which is the age where initial motor deficit symptoms are present (termed ‘post-onset’; [10, 20]). These treatments were continued weekly throughout until the end-stage of disease (i.e. point of euthanasia for survival). Another cohort of animals was treated with control IgG2b or anti-HMGB1 antibody from 35 days till 133 days postnatal (termed ‘mid-symptomatic stage’), where spinal cord and skeletal muscles were collected for quantitative PCR and immunohistochemistry analysis to measure the degree of inflammation. To remove any potential bias, all antibody and vehicle treatments were coded, and then administered and subsequently analysed by a researcher (JDL) blinded to the treatment groups. Blinding was conducted in a manner such that neither the experimenter, nor the entire research team were aware of the treatment code. De-coding only occurred after all animal experiments were completed.

Survival analysis and motor score

Survival was determined by the inability of the animal to right itself within 15–30 s if laid on either side. This is a widely accepted endpoint for life span studies in ALS mice [21, 22] and guarantees that euthanasia occurs prior to the mice being unable to reach food or water. A motor score was assigned to each mouse weekly, reflecting their motor function based on the presentation of hind-limb tremor, gait abnormalities, hind-limb splay, hind-limb paralysis and presence of the righting reflex [23]. Each factor was assigned a value of 0 or 1, corresponding to normal and abnormal phenotype respectively. An exception to this was the hind-limb splay and

---

Lee et al. Journal of Neuroinflammation (2019) 16:45

Page 2 of 12
righting reflex, which ranged from 0, 1 and 2, coinciding with normal splay and 0 s, partially collapsed to the lateral midline and below 5 s and completely collapsed to the lateral midline and greater than 15 s for hind-limb splay and righting reflex time respectively. Each parameter was scored and summated to calculate the motor score for each mouse (Table 1).

Weight measurements and hind limb grip strength test
Isotype control and anti-HMGB1 antibody-treated SOD1<sup>G93A</sup> mice were weighed weekly at the same time of day (1600–1800 h), from 42 days of age until the defined end-stage (loss of righting reflex). A digital force gauge (Ugo Basile) was used to measure maximal hind-limb muscle grip strength. Mice were held by their tail and lowered until their hind limbs grasped the T-bar connected to the digital force gauge. The tail was then lowered until the body was horizontal with the apparatus, and mice gently pulled away from the T-bar with a smooth steady motion until both of their hind limbs released the bar. The strength of the grip was measured in gram force. Each mouse was given ten attempts and the maximum grip strength from these attempts recorded [20].

Tissue preparation for microglia/astrocyte quantification and immunohistochemistry
Isotype control or anti-HMGB1 antibody-treated SOD1<sup>G93A</sup> mice at mid-symptomatic stage (<i>n</i> = 4 per treatment group) were euthanized by intraperitoneal injection of zolazepam (50 mg/kg; Zoletil, Lyppard) and xylazine (10 mg/kg; Xylazil, Lyppard). Mice were then fixed by transcardiac perfusion with 2% sodium nitrite in 0.1 M phosphate buffer (pH 7.4; Sigma-Aldrich, St Louis, MO, USA) followed by 4% paraformaldehyde in 0.1 M phosphate buffer (4% PFA-PB, pH 7.4; Sigma-Aldrich, St Louis, MO, USA). Lumbar spinal cords were collected and placed into 4% PFA-PB for 2 h at 4 °C. Following this incubation, spinal cords were washed 3 × 5 min in phosphate-buffered saline (PBS; pH 7.4), followed by submersion in sucrose solution at 15% then 30% in PBS (pH 7.4). Lumbar spinal cords were then embedded in optimal cutting temperature compound (Sakura, Finetek, Torrance, CA, USA) then snap frozen in liquid nitrogen. Lumbar spinal cords were sectioned into 16-μm-thick transverse and coronal sections and dry mounted onto Superfrost Plus slides (Menzel-Glaser, Braunschweig, Germany) for quantification of astrocytes and microglia as detailed below.

Estimation of astrocytes and microglia
For estimation of astrocytes and microglia within the lumbar spinal cord, sections were rehydrated in PBS (pH 7.4) then blocked in PBS containing 3% bovine serum albumin (BSA) for 1 h at room temperature. Sections were incubated overnight at 4 °C with the astrocyte (mouse anti-GFAP; 1:1000, BD Biosciences, San Diego, CA, USA) and microglia (rat anti-CD11b; 1:500, Abcam, Cambridge, MA, USA) markers. Sections were washed with PBS for 3 × 10 min prior to incubation overnight at 4 °C with the Alexa secondary cocktail: Alexa Fluor 555 dye-conjugated goat anti-rat (1:1000, Invitrogen, Eugene, OR, USA) and Alexa Fluor 488 dye-conjugated goat anti-mouse (1:600, Invitrogen, Eugene, OR, USA) antibody. All primary and secondary antibodies were diluted in PBS (pH 7.4) containing 1% BSA. Sections were then washed for 3 × 5 min in PBS, then mounted with Prolong Gold Anti-Fade medium containing 4,6-diamidino-2-phenylindole (DAPI; Invitrogen, Eugene, OR, USA). Quantification of GFAP and CD11b immunostaining was performed on ~11 to 14 lumbar spinal cord sections spaced 320 μm apart and expressed as the percentage immunoreactive area per section [24]. Quantification was performed within the second lumbar dorsal root ganglia (L2) to the fifth lumbar dorsal root ganglia (L5), selected with the aid of the mouse spinal cord atlas [25]. Staining procedures and image exposures were all standardised between treatment groups and between sections. The treatment groups were not made available to the researchers until the completion of the study.

Quantification of activated microglia numbers
The cell body of microglia was labelled with the nuclear marker, DAPI. As microglia are known to display morphological changes when they become activated, such as an increase in cell body size, thickening of proximal processes and a decrease in the ramification of distal branches [26], activated microglia were defined by (i) the presence of one DAPI stain, (ii) an amoeboid cell body and (iii) proximal processes length ≤ 1–2 μm [27]. The

---

**Table 1** Summary of phenotypic observations used to assign motor scores

| Phenotype               | Score 0   | Score 1                                      | Score 2                                      |
|-------------------------|-----------|---------------------------------------------|---------------------------------------------|
| Hind-limb tremor        | Normal    | Tremor                                      | N/A                                         |
| Gait abnormalities      | Normal    | Gait abnormalities                          | N/A                                         |
| Hind-limb splay         | Normal    | Partially collapsed to the lateral midline  | Completely collapsed to the lateral midline  |
| Hind-limb paralysis     | Normal    | Dragging hind-limbs                         | N/A                                         |
| Righting reflex         | 0 s       | < 5 s                                       | > 15 s                                      |

---
total number of activated microglia was determined by the average of 11–14 sections, with the overall average multiplied by the number of sections within L2–L5 regions. The treatment groups were not made available to the researchers until quantification was completed.

Real-time quantitative PCR
Total RNA was isolated from lumbar spinal cord, gastrocnemius and tibialis anterior muscle of isotype control and anti-HMGB1 antibody-treated SOD1G93A mice using an RNeasy Lipid Tissue extraction kit according to manufacturer’s instructions (QIAGEN, CA, USA). Total RNA was purified from genomic DNA contamination using Turbo DNAse treatment (Ambion, NY, USA), then converted to cDNA using AffinityScript cDNA synthesis kit according to manufacturer’s instructions (Agilent Technologies, CA, USA). Commercially available gene-specific Taqman probes for integrin alpha M (Itgam; Mm00434455_m1), CD68 antigen (CD68; Mm03047343_m1), allograft inflammatory factor 1 (Aif1; Mm00479862_g1), lymphocyte antigen 6 complex, locus C1 (Ly6c1/Ly6c2; Mm0309946_m1), glial fibrillary acidic protein (Gfap; Mm01253033_m1), tumour necrosis factor (Tnf; Mm00443258_m1), interleukin 1 beta (I1b; Mm00434228_m1), advanced glycosylation end product-specific receptor (Ager; Mm01134790_g1), complement component 5a receptor 1 (C5ar1; Mm00500292_s1) and toll-like receptor 4 (Tlr4; Mm00445273_m1) were used to amplify target gene of interest (Applied Biosystems, MA, USA). Relative target gene expression to geometric mean of reference genes (Gapdh and Actb) was determined using this formula: \(2^{-\Delta CT} \) where \(\Delta CT = (Ct_{\text{target gene}} - Ct_{\text{Gapdh and Actb}})\); as per our previous studies [24, 28]. Final measures are presented as relative levels of gene expression in anti-HMGB1 antibody-treated SOD1G93A mice compared with expression in isotype control-treated mice. Probe sets were tested over a serial cDNA concentration for amplification efficiency. No reverse transcription, and water as no template control, was used as negative controls. All samples were run in triplicate and were tested in three separate experiments.

Statistical analysis
All analyses were performed using GraphPad Prism 7.0 (San Diego, CA, USA). The statistical difference for survival analyses between isotype control and anti-HMGB1 antibody-treated SOD1G93A mice were analysed using log rank (Mantel-Cox) test. The statistical difference between isotype control and anti-HMGB1 antibody-treated SOD1G93A mice for body weight, hind-limb grip strength and motor score were analysed using a two-way ANOVA and a post-hoc Bonferroni’s multiple comparisons test for each time point. For the results from GFAP and CD11b quantification and quantitative real-time PCR, statistical difference between isotype control and anti-HMGB1 antibody-treated SOD1G93A mice were determined using two-tailed student t test. All data are presented as mean ± SEM and the differences were considered significant when \(P < 0.05\).

Results
Pre-onset anti-HMGB1 antibody treatment transiently improves hind-limb grip strength but does not extend survival in SOD1G93A mice
In the first treatment study, a cohort of litter-matched SOD1G93A mice was administered isotype control, or anti-HMGB1 antibody treatment from 35 days of age onwards. At this age, SOD1G93A mice do not have any motor neuron loss [20]. SOD1G93A mice treated with anti-HMGB1 antibody from this ‘pre-onset’ age had no significant extension in survival time when compared with litter-matched untreated SOD1G93A mice (\(P = 0.3620, n = 13\); Fig. 1a). There was also no difference in body weight loss between isotype control and anti-HMGB1 antibody-treated SOD1G93A mice (\(P > 0.05, n = 13\); Fig. 1b). Motor deficits were also assessed in these animals using motor score and hind-limb grip strength. Anti-HMGB1 antibody treatment showed no improvement in motor scores when compared to control antibody-treated SOD1G93A mice (\(P > 0.05, n = 13\); Fig. 1c); however, anti-HMGB1 antibody treatment significantly counteracted the loss of hind limb grip strength earlier in the disease at 56 and 63 days of age when compared to control antibody-treated SOD1G93A mice (\(P < 0.05, +P < 0.0001, n = 13\); Fig. 1d).

Post-onset anti-HMGB1 antibody treatment does not extend survival or improve motor performance in SOD1G93A mice
We next determined if HMGB1 inhibition at a later stage of disease could reduce ALS pathology in mice. SOD1G93A mice were therefore treated with anti-HMGB1 antibody (100 μg) at 70 days of age, when there is considerable decline in motor performance and motor neuron loss in the SOD1G93A mouse model [20]. Anti-HMGB1 antibody treatment in SOD1G93A mice from this post-onset disease age showed no change in survival time compared to litter-matched control antibody-treated SOD1G93A mice (\(P = 0.6384, n = 12\); Fig. 2a). Similar to the pre-onset treatment group, post-onset anti-HMGB1 antibody treatment did not affect body weight loss in SOD1G93A mice (\(P > 0.05, n = 12\); Fig. 2b). Post-onset anti-HMGB1 antibody treatment also did not significantly improve motor score and
hind-limb grip strength loss in SOD1\textsuperscript{G93A} mice \((p > 0.05, n = 12); \text{Fig. 2c and d}).

**Anti-HMGB1 antibody treatment does not alter microglia and astrocytes in the spinal cord of SOD1\textsuperscript{G93A} mice**

Given previous studies demonstrating a potential role of microglia and astrocytes during disease progression of ALS [29–32], and the potential role for HMGB1 in modulating gliosis [33], we also examined glial markers in the pre-onset treatment group. We first investigated whether inhibition of HMGB1 in SOD1\textsuperscript{G93A} mice had any effect on microglia and astrocytes in the lumbar spinal cord. mRNA expression levels of Itgam, Cd68 and Aif1 (markers of both resident microglia and infiltrating monocyte/macrophages) and Ly6c (predominant marker of early infiltrating monocyte/macrophages) were measured in the lumbar spinal cord of isotype control and anti-HMGB1 antibody-treated SOD1\textsuperscript{G93A} mice at mid-symptomatic stage of disease progression using quantitative real-time PCR. Itgam, Cd68 and Aif1 transcripts were unaltered in anti-HMGB1 antibody-treated SOD1\textsuperscript{G93A} mice when compared to control antibody-treated SOD1\textsuperscript{G93A} mice \((n = 6, p > 0.05); \text{Fig. 3a–c}). However, Ly6c transcripts were significantly reduced in anti-HMGB1 antibody-treated SOD1\textsuperscript{G93A} mice when compared to control antibody-treated SOD1\textsuperscript{G93A} mice \((n = 6, *p < 0.05); \text{Fig. 3d}). Microglial activation was also examined using immunofluorescence. No change in immunoreactive area of CD11b-positive microglia, and the number of activated microglia in the lumbar spinal cord of control or anti-HMGB1 antibody-treated SOD1\textsuperscript{G93A} mice were found at mid-symptomatic stage of disease \((n = 4, p > 0.05); \text{Fig. 3e, f}). Next, we investigated the mRNA expression levels of Gfap (marker of astrocytes) in the lumbar spinal cord of isotype control and anti-HMGB1 antibody-treated SOD1\textsuperscript{G93A} mice at mid-symptomatic stage of disease. Gfap transcript was also unaltered in anti-HMGB1 antibody-treated SOD1\textsuperscript{G93A} mice when compared to control antibody-treated SOD1\textsuperscript{G93A} mice \((n = 6, p > 0.05); \text{Fig. 3g}). These results were also confirmed using immunofluorescence, where the immunoreactive area of GFAP-positive astrocytes did not change between control
and anti-HMGB1 antibody-treated SOD1\textsuperscript{G93A} mice (\(n = 4\), \(p > 0.05\); Fig. 3h).

**Anti-HMGB1 antibody treatment reduces TNF\(\alpha\) and C5aR1 gene expression in the spinal cord of SOD1\textsuperscript{G93A} mice**

Activation of HMGB1 also induces synthesis of cytokines to modulate inflammatory processes, and has been shown to induce cytokine expression in microglia [34]. Importantly, pro-inflammatory cytokines such as TNF\(\alpha\) and IL-1\(\beta\) are thought to propagate disease progression in ALS through the activation of the innate immune system [35]. Hence, we investigated whether inhibition of HMGB1 in SOD1\textsuperscript{G93A} mice had any effect on the expression of TNF\(\alpha\) and IL-1\(\beta\) and the several major receptors of the innate immune system (RAGE, complement C5aR1 and TLR4) in the lumbar spinal cord.

mRNA expression of Tnf and Il1\(\beta\) was measured in isotype control and anti-HMGB1 antibody-treated SOD1\textsuperscript{G93A} mice at mid-symptomatic stage of disease progression by quantitative real-time PCR. Tnf transcripts were significantly reduced in anti-HMGB1 antibody-treated SOD1\textsuperscript{G93A} mice by 0.27-fold when compared to control antibody-treated SOD1\textsuperscript{G93A} mice (\(n = 6\), **\(p < 0.01\); Fig. 4a), while Il1\(\beta\) mRNA expression did not change between control and anti-HMGB1 antibody-treated SOD1\textsuperscript{G93A} mice (\(n = 6\), \(p > 0.05\); Fig. 4b). There was no change in the mRNA expression of Ager and Tlr4 in the lumbar spinal cord of anti-HMGB1 antibody-treated SOD1\textsuperscript{G93A} mice when compared to control antibody-treated SOD1\textsuperscript{G93A} mice (\(n = 6\), \(p > 0.05\); Fig. 4c, d). However, C5ar1 mRNA expression was decreased by 0.22-fold in anti-HMGB1 antibody-treated SOD1\textsuperscript{G93A} mice when compared to control antibody-treated SOD1\textsuperscript{G93A} mice (\(n = 6\), *\(p < 0.05\); Fig. 4e). Taken together, these results suggest that HMGB1 inhibition reduces certain pro-inflammatory factors in the spinal cord of SOD1\textsuperscript{G93A} mice treated with anti-HMGB1 antibody at mid-symptomatic stage of disease.

**Anti-HMGB1 antibody treatment reduced monocyte markers in the tibialis anterior muscle of SOD1\textsuperscript{G93A} mice**

Given HMGB1’s role as a chemoattractant for leukocytes, and the known role of monocytes/macrophages accumulation in skeletal muscle denervation in SOD1\textsuperscript{G93A} mice [36, 37], we investigated whether neutralising HMGB1 in SOD1\textsuperscript{G93A} mice impacted on peripheronal monocytes/macrophages infiltration. mRNA expression levels of Itgam, Cd68, Aif1 (monocyte/macrophage marker) and Ly6c (monocyte marker) were
measured in the tibialis anterior (TA) and gastrocnemius (GN) muscles of isotype control and anti-HMGB1 antibody-treated SOD1<sup>G93A</sup> mice. SOD1<sup>G93A</sup> mice were intraperitoneally injected weekly with the anti-HMGB1 antibody at 35 days of age (100 μg). Major non-neuronal cell populations (microglia/monocytes and astrocytes) in vehicle and anti-HMGB1-treated SOD1<sup>G93A</sup> mice were investigated at mid-symptomatic stage of disease (133 days) using quantitative PCR and immunohistochemistry. a–c Shows anti-HMGB1 treatment had no effect on microglia (Itgam, Cd68 and Aif1) mRNA transcript levels (n = 6, p > 0.05, Student’s t test). d Shows a reduction in monocyte (Ly6c) mRNA transcript levels in anti-HMGB1-treated SOD1<sup>G93A</sup> mice when compared to isotype control-treated SOD1<sup>G93A</sup> mice (n = 6, *p < 0.05, Student’s t test). e Shows representative images of CD11b-positive microglia in the lumbar spinal cord of isotype control and anti-HMGB1-treated SOD1<sup>G93A</sup> mice at 133 days of age. Dashed line shows the outline of the ventral horn with higher magnification of the white square. Scale bar = 100 μm. f, g Shows no change in microglia expression and activated microglia (amoeboid) in anti-HMGB1-treated SOD1<sup>G93A</sup> mice compared with isotype control-treated SOD1<sup>G93A</sup> mice (n = 4, p > 0.05, Student’s t test). h Shows no change in astrocyte (Gfap) mRNA transcript levels between isotype control and anti-HMGB1-treated SOD1<sup>G93A</sup> mice (n = 6, p > 0.05, Student’s t test). i Show representative images of GFAP-positive astrocytes in the lumbar spinal cord of isotype control and anti-HMGB1-treated SOD1<sup>G93A</sup> mice at 133 days of age. Dashed line shows the outline of the ventral horn with higher magnification of the white squares. Scale bars = 100 μm. j Shows no change in astrocyte expression in anti-HMGB1 treated-SOD1<sup>G93A</sup> mice compared with isotype control-treated SOD1<sup>G93A</sup> mice (n = 4, p > 0.05, Student’s t test). Data are presented as mean ± SEM.
same panel of inflammatory and innate immune markers as used in the spinal cord, in the skeletal muscles. Interestingly, unlike the spinal cord, anti-HMGB1 antibody treatment did not change cytokines (Tnf and IL1β) or innate immune receptors (Ager and C5ar1) in both TA and GN muscles of SOD1<sup>G93A</sup> mice but had slight reduction of Tlr4 transcript in TA muscle (n = 6, *p < 0.05; Fig. 6a–e).

**Discussion**

Although the exact mechanisms that underlie the pathogenesis of ALS remain unclear, there is credible evidence that a co-ordinated action of innate and adaptive immune factors, both in the periphery and the central nervous system, may contribute substantially in the progression of ALS. This includes evidence for major innate immune systems such as the complement cascade...
at the level of C5a/C5aR1, the TLR system and RAGE, where it is shown that these immune receptors promote neuroinflammation and disease progression of ALS [6–11, 20, 24, 37, 38]. HMGB1 is an ubiquitous nuclear protein that is released extracellularly after cellular stress, damage and death and promotes inflammation by binding to innate immune receptors such as TLR2, TLR4 and RAGE, suggesting that it could play a role in the disease progression of ALS. In support of this, previous studies have demonstrated that TLR2, TLR4 and RAGE are significantly increased on microglia and astrocytes during ALS progression in SOD1 G93A mice, and inhibition/ablation of these components have beneficial effects on the disease outcome [6–9, 16]. In addition, we previously demonstrated increased HMGB1, the ligand for TLR2, TLR4 and RAGE, in the spinal cord of SOD1 G93A mice, and inhibition/ablation of these components have beneficial effects on the disease outcome [6–9, 16].

HMGB1 is a highly conserved nuclear protein made up of 215 residues consisting of 2 DNA-binding domains (termed A- and B-boxes) with a highly negatively charged C-terminal tail. The monoclonal anti-HMGB1 2G7 antibody used in our study recognises an epitope in the box A domain and has been previously characterised to show neutralising activity of HMGB1 [39]. Furthermore, this anti-HMGB1 antibody has been shown to neutralise the cytokine isoform of HMGB1 [40]. To determine the effect of HMGB1 neutralisation in SOD1 G93A mice disease progression, antibody treatment experiments included mice injected from an early pre-symptomatic age (day 35) to determine the maximum effect of HMGB1 inhibition, as well as at a later onset time point where motor deficits are first evident (day 70). The present study demonstrated that neutralisation of HMGB1 via an intraperitoneal injection of anti-HMGB1 2G7 antibody at both time points did not extend survival time, however transiently improved the early motor deficits and reduced inflammation in the spinal cord of SOD1 G93A mice with pre-onset treatment. This is consistent with previous studies using monoclonal anti-HMGB1 2G7 antibody in experimental rodent models of stroke and lupus nephritis where minimal efficacy was observed. For stroke, there was no reduction in infarct volume or improvement in neurological outcomes, following anti-HMGB1 2G7 treatment, although some alleviated sickness behaviour was documented due to reductions in peripheral immune responses [41]. For nephritis, there were no changes in disease parameters.
including kidney pathology, body weight and proteinuria [42]. However, other studies have demonstrated that HMGB1-blocking therapies show beneficial effects in providing significant protection following traumatic brain injury, arthritis, experimental sepsis and liver injury [19, 43–47]. One explanation for the apparent lack of efficacy of HMBG1 neutralisation in the present study, despite the fact that TLR2, TLR4 and RAGE inhibition in SOD1 GG93A mice is documented to be beneficial, is that there are other endogenous ligands activating TLR2, TLR4 and RAGE, which could contribute to disease pathology. Indeed, in ALS, other endogenous ligands for these innate immune receptors, such as heat shock protein 60 (HSP60), HSP70 and S100β protein, have been implicated in disease progression of ALS and their inhibition reduces inflammation and ALS disease parameters, suggesting they could contribute to the disease pathogenesis through TLR or RAGE activation. Our results indicate therefore that HMGB1 activation of TLR2, TLR4 and RAGE in SOD1 GG93A mice may be compensated for by other endogenous ligands, which may explain the lack of efficacy on survival with anti-HMGB1 antibody treatment. Furthermore, others have also suggested that astrocytic HMGB1 signalling in ALS could be neuro-protective via release of neurotrophic factors such as brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor [48]. Anti-HMGB1 antibody treatment also demonstrated no alteration in microglia/macrophages and astrocytes which supports the lack of beneficial effect on disease progression and survival in treated animals. Small reductions in pro-inflammatory cytokines TNFα and innate immune receptors C5aR1 and TLR4 in lumbar spinal cord and skeletal muscle however were observed, indicating that treated mice did have some alterations in inflammatory biomarkers. One limitation of this study is the use of an antibody approach to target HMGB1. Antibodies are known to have limited brain and spinal cord penetration [49], which may have impacted on the potential inhibitory effect of the compound on CNS-derived HMGB1. However, we have previously shown that SOD1 GG93A mice have a leaky blood-brain barrier/blood-spinal cord barrier early in the disease, which progresses until end-stage [10], and other antibody approaches have been successfully used in SOD1 GG93A models previously [50]. Furthermore, the reductions in the spinal cord inflammatory markers, C5aR1 and TNFα, suggest that some localised HMGB1 blockade was occurring. Regardless, future investigation of the plasma and CNS pharmacokinetic profile of anti-HMGB1 2G7 antibody is warranted to confirm concentrations in the target tissues following our dosage regime.

Conclusions

In summary, the present study demonstrated that early neutralisation of extracellularly released HMGB1 with an anti-HMGB1 antibody in SOD1 GG93A ALS mice transiently improves hind-limb grip strength, associated with reduced spinal cord expression of key pro-inflammatory genes. However, anti-HMGB1 treatment had no effect on motor decline or survival, and did not alter spinal cord glial numbers or activation profiles, suggesting a minimal role for this DAMP in overall neuroinflammation and disease progression. These data therefore indicate that HMGB1 signalling plays a minor role in the SOD1 GG93A model of ALS, limiting the further exploration of targeted HMGB1 inhibition with antibodies such as 2G7, as a treatment for ALS.

Abbreviations

ALS: Amyotrophic lateral sclerosis; C5aR1: Complement C5a receptor 1; CNS: Central nervous system; DAMP: Danger-associated molecular pattern; GN: Gastrocnemius muscle; HMGB1: High-mobility group box 1; RAGE: Receptor for advanced glycation end products; TA: Tibialis anterior muscle; TLR: Toll-like receptor

Acknowledgements

The authors would like to sincerely thank Kym French for the animal care and husbandry. We also thank Maryam Shayegh for her technical support with genotyping mice.

Funding

JDL holds a Motor Neuron Disease Research Institute of Australia (MNDRIA) Postdoctoral Fellowship (PDF1604), and the research was funded by the Fat Rabbit MND Research Grant from the MNDRIA (to TMW, JDL and UA; GIA1728). TMW is supported by a NHMRC Career Development Fellowship (APP1105420), HEH have support from the Swedish research council.

Availability of data and materials

Not applicable.

Authors’ contributions

JDL, UA and TMW conceived the project. JDL and TMW designed the study. JDL performed the majority of the experiments with assistance by NL and SCL. LO and HEH generated the blocking antibodies used in the project. All authors contributed to the analyses and/or interpreted the data. JDL wrote the paper with contribution from TMW. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All experimental procedures were approved by the University of Queensland Animal Ethics Committee and complied with the policies and regulations regarding animal experimentation. They were conducted in accordance with the Queensland Government Animal Research Act 2001, associated Animal Care and Protection Regulations (2002 and 2008) and the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 8th Edition (National Health and Medical Research Council, 2013). ARRIVE guidelines have been followed in the preparation of the manuscript.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author details

1. Faculty of Medicine, School of Biomedical Sciences, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia. 2. Faculty of Medicine, University of Queensland Centre for Clinical Research, The University of Queensland, Herston, Brisbane, QLD 4029, Australia. 3. Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden. 4. Centre for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Received: 16 November 2018 Accepted: 13 February 2019

Published online: 19 February 2019

References

1. Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3(1):7085.

2. Brennan FH, Lee JD, Ruitenberg MJ, Woodruff TM. Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. Semin Immunol. 2016;28:292–308.

3. McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in ALS. Curr Mol Med. 2011;11:246–54.

4. Zarei S, Kerr K, Reiley L, Diaz K, Guerra O, Altamirano PF, Pagani W, Lodin D, Orozco G, Chinae A. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6:171.

5. Brites D, Vaz AR. Microglia centered pathogenesis in ALS insights in cell interconnectivity. Front Cell Neurosci. 2014;8:117.

6. Lee JY, Lee JD, Phipps S, Noakes PG, Woodruff TM. Absence of toll-like receptor 4 (TLR4) extends survival in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2015;12:90.

7. De Paola M, Mariani A, Bigini P, Peviani M, Ferrara G, Molteni M, Gemma S, Vegliante F, Castellaneta V, Boldrin V, et al. Neuroprotective effects of toll-like receptor 4 antagonist in spinal cord cultures and in a mouse model of motor neuron degeneration. Mol Med. 2012;18:971–81.

8. Feller A, Barhum Y, Angel A, Perets N, Steiner I, Offen D, Lev N. Toll-like Receptor-4 inhibitor TAK-242 attenuates motor dysfunction and spinal cord pathology in an amyotrophic lateral sclerosis mouse model. Int J Mol Sci. 2017;18.

9. Jurkiewicz JK, Daffu GK, Geddiss MS, Li H, Rosario R, Kaplan BJ, Kelly L, Schmidt AM. Soluble RAGE treatment delays progression of amyotrophic lateral sclerosis in SOD1 mice. Front Cell Neurosci. 2016;10:117.

10. Lee JD, Kumar V, Fung JN, Ruitenberg MJ, Noakes PG, Woodruff TM. Pharmacological inhibition of complement C5a-C5aR1 receptor signalling ameliorates disease pathology in an amyotrophic lateral sclerosis mouse model. Br J Pharmacol. 2017;174:689–99.

11. Woodruff TM, Lee JD, Noakes PG. Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proc Natl Acad Sci U S A. 2014;111:E3–4.

12. Ray R, Jurkiewicz JK, Rai V. RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis. Neurosci Biobehav Rev. 2016;62:448–55.

13. Persson U, Yang H, Harris E. Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opin Ther Targets. 2018;22:263–77.

14. Persson U, Yang H, Harris E. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Semin Immunol. 2018;38:40–9.

15. Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 develops enhanced neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice. Hepatology. 2016;64:1699–710.

16. Lee JD, Kamaruzaman NA, Fung JN, Taylor SM, Turner BJ, Atkin JD, Woodruff TM, Noakes PG. Dysregulation of the complement cascade in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2013;10:119.

17. Slupsky AC, Bhandari A, Blaugrund E, Henggeler B, Loffler JP, Martinek J, Weininger V, Meyer T, Moussac M, Robberecht W, et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler. 2007;8:217–23.

18. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, Bostrom A, Theodoss J, Al-Nakhala BM, Vieira FG, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotrophic Lateral Scler. 2008;9:4–15.

19. Hatzirepetos T, Kidd JD, Moreno AJ, Thompson K, Gill A, Vieira FG. A quick phenotypic neurological scoring system for evaluating disease progression in the SOD1(G93A) mouse model of ALS. J Vis Exp. 2015(104).

20. Lee JD, Levin SC, Willis EF, Li R, Woodruff TM, Noakes PG. Complement components are upregulated and correlate with disease progression in the TDP-43(Q331K) mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2018;15:171.

21. Watson C, Paxios G, Kalyanoglu G. The Spinal Cord. First ed. London: Academic Press; 2009.

22. Li G, Bares BA. Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol. 2018;18:252–62.

23. Phillips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10:253–63.

24. Chand KK, Lee KM, Lee JD, Qiu H, Willis EF, Lavidi NS, Hilliard MA, Noakes PG. Deficits in synaptic transmission at the neuromuscular junction precede motor deficits in a TDP-43(Q331K) transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2018;32:2676–89.

25. Arbour D, Van de Velde C, Robotaille R. New perspectives on amyotrophic lateral sclerosis: the role of glial cells at the neuromuscular junction. J Physiol. 2017;595:647–61.

26. Celoso MC, Corvino V, Marchese E, Serrano A, Michetti F, D’Ambrosi N. The dual role of microglia in ALS: mechanisms and therapeutic approaches. Front Aging Neurosci. 2017;9:242.

27. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, et al. Neuronal reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–7.

28. Philips T, Rothstein JD. Glial cells in amyotrophic lateral sclerosis. Exp Neurol. 2014;262 Pt B:111–20.

29. Fang P, Schachner M, Shen YQ. HMGB1 in development and diseases of the central nervous system. Mol Neurobiol. 2012;45:499–506.

30. Glass CK, Saajo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying neuroinflammation in neurodegeneration. Cell. 2010;140:19–34.

31. Phani S, Re DB, Przedborski S. The role of the innate immune system in ALS. Front Pharmacol. 2012;3:150.

32. Schiraldi M, Raucci A, Munoz LM, Liveti V, Celona B, Venereau E, Apuzzo T, De Marchis F, Pedotti M, Bach A, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med. 2012;210:531–63.

33. Wang HA, Lee JD, Lee KM, Woodruff TM, Noakes PG. Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Skelet Muscle. 2017;7:10.

34. Woodruff TM, Costantini KJ, Crane JW, Atkin JD, Monk PN, Taylor SM, Noakes PG. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008;181:18727–34.

35. Ucott H, Lundberg J, Salo H, Klevensilv L,Damberg P, Ottosson L, Andersson U, Holmén S, Eranson Harris H. Neuroinflammation in response to intracerebral injections of different HMGB1 redox isoforms. J Innate Immun. 2018;10:215–27.

36. Yang H, Hrengviddithos HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-Abed Y, et al. A critical cytokine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A. 2010;107:11942–7.

37. Liesz A, Dalpke A, Marasco E, Antoine DJ, Roth S, Zhou W, Yang H, Na SY, Akhisaroglu M, Fleming T, et al. DAMP signalling is a key pathway inducing immune modulation after brain injury. J Neurosci. 2015;35:583–98.

38. Schaper F, Van Timmeren MM, Petersen A, Horst G, Bijn M, Limburg PC, Westra J, Heeringa P. Treatment with anti-HMGB1 monoclonal antibody does not affect lupus nephritis in MRL/lpr mice. Mol Med. 2016;22:12–21.
43. Kim JB, Sig Choi J, Yu YM, Nam K, Piao CS, Kim SW, Lee MH, Han PL, Park JS, Lee JK. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci. 2006;26:6413-21.

44. Muhammad S, Barakat W, Stoyanov S, Munkirati S, Yang H, Tracey KJ, Bendzus M, Rossetti G, Nawroth PP, Bierhaus A, Schwaninger M. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci. 2008;28:12023-31.

45. Okuma Y, Liu K, Wake H, Zhang J, Manuo T, Date I, Yoshino T, Ohtsuka A, Otani N, Tomura S, et al. Anti-high mobility group box-1 antibody therapy for traumatic brain injury. Ann Neurol. 2012;72:362-73.

46. Schierbeck H, Lundback P, Palmblad K, Klevenvall L, Erlandsson-Harris H, Andersson U, Ottosson L. Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med. 2011;17:1039-44.

47. Valdes-Ferrer SI, Rosas-Ballina M, Olofsson PS, Lu B, Dancho ME, Ochani M, Li JH, Scheinerman JA, Katz DA, Levine YA, et al. HMGB1 mediates splenomegaly and expansion of splenic CD11b+ Ly-6C(high) inflammatory monocytes in murine sepsis survivors. J Intern Med. 2013;274:381-90.

48. Brambilla L, Martorana F, Guidotti G, Rossi D. Dysregulation of astrocytic HMGB1 signaling in amyotrophic lateral sclerosis. Front Neurosci. 2018;12:622.

49. Freskgard PO, Urich E. Antibody therapies in CNS diseases. Neuropharmacology. 2017;120:38-55.

50. Bros-Facer V, Krull D, Taylor A, Dick JR, Bates SA, Cleveland MS, Prinjha RK, Greensmith L. Treatment with an antibody directed against Nogo-a delays disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Hum Mol Genet. 2014;23:4187-200.